At BIO Asia–Taiwan 2025, LumiSTAR Biotechnology and Molecular Devices (HK) hosted a cutting-edge Satellite Symposium on Next-Generation Approaches in Drug Development, spotlighting iPSC-derived disease models, high-throughput screening, and neuroscience drug innovation.

Yu-Fen Chang, CEO and founder of LumiSTAR Biotech, revealed how patient-derived iPSC 3D brain models (Alzheimer’s, Parkinson’s) using astrocytes, glial cells, and beta-amyloid aggregation offer a more realistic and translatable drug testing platform.

Expert speakers from Genomics Research Center, Academia Sinica, Molecular Devices, Eurofins Discovery and Osaka University showcased an integrated pipeline—from hashtag#cardiotoxicity testing to regenerative medicine—ushering in a new era of animal testing alternatives.

As FDA shifts toward human-relevant models, Taiwan and Japan’s research powerhouses are driving the next frontier in translational medicine.

Explore more: https://lnkd.in/gi68Gu7K

Speakers:
Rachel Cheng (Genomics Research Center of Academia Sinica)
Bella Tsai (Molecular Devices)
Elsa Liu (Eurofins Discovery)
Li Liu (Osaka University)